(Total Views: 596)
Posted On: 05/28/2025 11:58:33 AM
Post# of 154603
Nothing to see here:
Quote:
Yes, GSK CEO Emma Walmsley discussed a groundbreaking cancer drug at the Wall Street Journal's Future of Everything Conference, which is taking place today and tomorrow, May 28-29, 2025, in New York City.
In her remarks, she highlighted Blenrep (belantamab mafodotin), an antibody-drug conjugate for relapsed or refractory multiple myeloma. She emphasized its three-year overall survival data, noting that it could change the standard of care in this setting. This aligns with previously released Phase III DREAMM-7 trial results, which showed a 42% reduction in the risk of death when Blenrep was combined with bortezomib and dexamethasone, compared to a standard daratumumab-based regimen.
(6)
(0)
